Vonoprazan‐based therapies versus PPI‐based therapies in patients with H. pylori infection: Systematic review and meta‐analyses of randomized controlled trials

Documenti analoghi

• Vonoprazan and amoxicillin dual therapy for 14 days as the first‐line treatment of Helicobacter pylori infection: A non‐inferiority, randomized clinical trial
  di: Yi Hu, et al.
  Pubblicazione: (2024)
• Application of cefuroxime in the eradication therapy of Helicobacter pylori infection: A review article
  di: Changmin Mi, et al.
  Pubblicazione: (2024)
• Research progress in photodynamic therapy for Helicobacter pylori infection
  di: Qian Luo, et al.
  Pubblicazione: (2024)
• Low‐dose or high‐dose amoxicillin in vonoprazan‐based dual therapy for Helicobacter pylori eradication? A systematic review and meta‐analysis
  di: Kun‐Ping Ju, et al.
  Pubblicazione: (2024)
• 14‐day tailored PCR‐guided triple therapy versus 14‐day non‐Bismuth concomitant quadruple therapy for Helicobacter pylori eradication: A multicenter, open‐label randomized noninferiority controlled trial
  di: Aurelien Amiot, et al.
  Pubblicazione: (2024)